HealthcareServices

Global Radiotheranostics Market 2026–2030: Forecast Insights for Business Planning

March 2, 2026March 2, 2026 by Marketing Posting

Uncover key drivers, emerging technologies, and competitive movements shaping the radiotheranostics market from 2026–2035 with trusted insights from The Business Research Company

How much larger will the Radiotheranostics Market be in 2030 compared with 2026?

The radiotheranostics market size has seen rapid growth in recent years. It is forecast to increase from $10.05 billion in 2025 to $11.43 billion in 2026, achieving a compound annual growth rate (CAGR) of 13.7%. This historical growth can be attributed to the increasing use of nuclear medicine diagnostics, the expansion of oncology-focused clinical research, the availability of therapeutic radioisotopes, the rising adoption of PET and SPECT imaging, and growing collaboration between pharma and imaging providers.

The radiotheranostics market is projected to experience substantial expansion over the coming years. Its valuation is set to reach $19.24 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 13.9%. This anticipated growth during the projection period stems from several factors, including the rising number of approvals for radiotheranostic drugs, increased investments in precision oncology, the broadening of isotope production infrastructure, the escalating need for personalized cancer care, and the greater integration of AI in selecting treatments. Key developments expected within this period encompass the wider embrace of targeted radioligand therapies, the increased application of paired diagnostic and therapeutic isotopes, the deepening integration of precision imaging with therapy, the enlargement of personalized oncology applications, and a heightened emphasis on targeting cancer at a molecular level.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=12270&type=smp

What Drivers Are Guiding Growth Patterns In The Radiotheranostics Market?

The rising incidence of cancer is anticipated to fuel the expansion of the radiotheranostics market in the future. Cancer is defined as a disease where certain body cells multiply without control and disseminate to various parts of the body. Radiotheranostics medications are frequently utilized in cancer treatment, providing the pinnacle of personalized medicine through the application of combined diagnostic and therapeutic radionuclide probes. These probes enable the precise and targeted identification and management of particular cells, often cancerous ones, with each approach tailored to the patient’s unique condition to boost treatment effectiveness and improve clinical outcomes. For example, data from January 2024, released by the American Cancer Society, a US-based nonprofit cancer advocacy group, indicated that cancer cases rose to 2,001,140, up from 1,958,310 in 2023, showing a 2.19% increase. Consequently, the growing occurrence of cancer acts as a key driver for the radiotheranostics market.

Which Segments Are Driving Activity In The Radiotheranostics Market?

The radiotheranostics market covered in this report is segmented –

1) By Radioisotope: Technetium-99, Gallium-68, Iodine-131, Iodine-123, Fludeoxyglucose-18F, Yttrium-90, Lutetium (Lu) 177, Copper (Cu) 67, Copper (Cu) 64, Other Radioisotopes

2) By Approach: Targeted Therapeutic, Targeted Diagnostic

3) By Application: Oncology, Non-Oncology

4) By End-Users: Hospitals And Clinics, Pharmaceutical And Biotechnology Companies, Other End-Users

Subsegments:

1) By Technetium-99: Technetium-99m, Technetium-99 Pertechnetate

2) By Gallium-68: Gallium-68 DOTATATE, Gallium-68 PSMA

3) By Iodine-131: Iodine-131 For Thyroid Cancer Treatment, Iodine-131 For Hyperthyroidism Treatment

4) By Iodine-123: Iodine-123 For Thyroid Scans, Iodine-123 For Cardiac Imaging

5) By Fludeoxyglucose-18F (FDG): FDG For Oncology Imaging, FDG For Brain Imaging

6) By Yttrium-90: Yttrium-90 Microspheres For Liver Cancer, Yttrium-90 For Radioimmunotherapy

7) By Lutetium (Lu) 177: Lutetium-177 PSMA For Prostate Cancer, Lutetium-177 DOTATATE For Neuroendocrine Tumors

8) By Copper (Cu) 67: Copper-67 For Targeted Radiotherapy, Copper-67 In Clinical Trials

9) By Copper (Cu) 64: Copper-64 For PET Imaging, Copper-64 For Radiotherapy

10) By Other Radioisotopes: Radium-223, Samarium-153, Other Emerging Radioisotopes In Theranostics

What Long-Term Trends Are Expected To Shape The Future Of The Radiotheranostics Market?

Leading companies operating within the radiotheranostics market are concentrating on developing innovative products to enhance the production and availability of therapeutic radioisotopes, improve the precision of treatments, and satisfy the growing demand for targeted cancer therapies. For instance, in May 2023, Advanced Cyclotron Systems Inc., a Canada-based company supplying and servicing cyclotrons predominantly used for producing medical isotopes, unveiled TR-ALPHA, a dedicated cyclotron engineered for producing alpha-emitting radioisotopes to treat cancer. Designed to fulfill the market’s requirement for a cost-effective cyclotron capable of manufacturing large quantities of Astatine-211, recognized as one of the most promising alpha-emitting radioisotopes, the TR-ALPHA is more compact, more affordable, and simpler to operate than earlier models, making it an ideal solution for hospitals, research institutions, and organizations aiming to efficiently produce therapeutic alpha-emitting radioisotopes.

Which Key Players Are Driving Competition In The Radiotheranostics Market?

Major companies operating in the radiotheranostics market are Lantheus Holdings Inc., Cardinal Health Inc., GE Healthcare Inc., Bayer AG, Novartis AG, Siemens Healthineers, Orano Med, Curium SAS, IBA Molecular, The Eckert & Ziegler Group, Advanced Accelerator Applications (AAA), Telix Pharmaceuticals Limited., Abdera Therapeutics, Blue Earth Diagnostics, Sirtex Medical Limited, Y-mAbs Therapeutics Inc., ITM Radiopharma, NorthStar Medical Radioisotopes LLC, Trasis S.A., Molecular Targeting Technologies Inc., RadioMedix Inc, Clarity Pharmaceuticals, Actinium Pharmaceuticals Inc., Navidea Biopharmaceuticals Inc.

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/radiotheranostics-global-market-report

Which Region Is Projected To Lead The Radiotheranostics Market During The Forecast Period?

North America was the largest region in the radiotheranostics market in 2025. The regions covered in the radiotheranostics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Radiotheranostics Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=12270&type=smp

Browse Through More Reports Similar to the Global Radiotheranostics Market 2026, By The Business Research Company

Oncologists Market Report 2026

https://www.thebusinessresearchcompany.com/report/oncologists-global-market-report

Diagnostic Radioisotopes Market Report 2026

https://www.thebusinessresearchcompany.com/report/diagnostic-radioisotopes-global-market-report

Radome Market Report 2026

https://www.thebusinessresearchcompany.com/report/radome-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795